跳至主要内容
临床试验/NL-OMON40712
NL-OMON40712已完成不适用

The role of (micro)vasculature and angiogenesis in inflammatory diseases of the human skin - (micro)vasculature and angiogenesis in inflammatory skin diseases

Dermatologie0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patients must meet the following criteria:
  • - Adults older than 18 years of age
  • - All patients have tot have chronique plaque psoriasis (i.e. psoriasis vulgaris)
  • - Patients must be willing to give a written informed consent
  • - Patients must be able to adhere to the visit schedule
  • - Applicable in fifty patients; The doctor and the patient decided that the best treatment option was photo therapy, clobetasol 17-proprionate, dithranol or anti-TNF treatment;Criteria voor vrijwilligers:
  • - Adults older than 18 years of age
  • - Volunteers must be willing to give written informed consent
  • - Volunteers must be able to adhere to the visit schedule

排除标准

  • Patients will be excluded from this study when any of the following criteria listed below are met:
  • - Children or adolescents younger than 18 years of age
  • - Patients with relevant co-morbidities
  • - Patients with another subtype of psoriasis than psoriasis vulgaris
  • - Patients with a history of signs of other (inflammatory) skin diseases, for example atopic dermatitis
  • - Patients who use medication with inhibitory effects on angiogenesis (for example Thalidomide (Softanon®), Sunitinib (Sutent®), COX-2 inhibitors as NSAIDs)
  • - Patients with co-morbidity that positively or negatively affects angiogenesis (such as microangiopathy and/or peripheral vascular disease in diabetics, smokers, etc)
  • - Use of anti-psoriatic medication before inclusion:
  • - Topical medication in the last 7 days
  • - Systemic medication or photo therapy within the last 4 weeks
  • - Patients with multiple (superficial) wounds and excoriations
  • - Patients with contra-indications for any kind of psoriatic treatment;Exclusion criteria for Healthy volunteers:
  • - Children or adolescents younger than 18 years of age
  • - Volunteers with relevant co-morbidities
  • - Volunteers with a history or signs of other (inflammatory) skin diseases, for example atopic dermatitis and psoriasis
  • - Volunteers who use medication with inhibitory effects on angiogenesis (for example Thalidomide (Softanon®), Sunitinib (Sutent®), COX-2 inhibitors as NSAIDs)
  • - Volunteers with co-morbidity that positively or negatively affects angiogenesis (such as micro-angiopathy and/or peripheral vascular disease in diabetics, smokers, etc)
  • - Volunteers with multiple (superficial) wounds and excoriations

研究者

发起方
Dermatologie

相似试验